Startup profile · funding coverage
Insitro
Machine learning-driven drug discovery company founded by Daphne Koller.
Stage
growth
Status
private
Coverage
full
Why Insitro is interesting
Insitro pairs ML with biology at scale — a marquee Bio+AI brand in the a16z orbit.
Key facts
- Series B (May 2020): $143M led by a16z with ARCH, Third Rock, Two Sigma (insitro press)
- Series C (Mar 2021): $400M led by CPP Investments; a16z, ARCH, Third Rock, Two Sigma returned (insitro press)
Investors in our directory
Funds linked from Insitro's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Insitro
Funding context and why this company shows up in venture coverage.
Insitro applies machine learning to large-scale biological data to discover and develop novel therapeutics.
Andreessen Horowitz (see /fund/andreessen-horowitz), ARCH Venture Partners (/fund/arch-venture-partners), Third Rock Ventures (/fund/third-rock-ventures), and Two Sigma Ventures (/fund/two-sigma-ventures) backed the company.
Insitro raised a $143M Series B in 2020 and a $400M Series C in 2021 led by CPP Investments (not in VCT directory).
Insitro is a marquee Bio+AI brand — founded by ML pioneer Daphne Koller with hundreds of millions raised to industrialize drug discovery.
Insitro remains private as of July 2026.
Last updated: 2026-07-24